Biocept Granted U.S. Patent for Blood Collection and Transport Tube
Expands patent protection for liquid biopsy platform
The granted patent covers Biocept's blood collection preservative
contained in the tube for collecting patient blood used for circulating
tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic analysis at
"This patent is highly complementary to the multiple patents we hold on
our microchannel technology both in the U.S. and overseas, and further
protects the unique solutions we are bringing to oncology and laboratory
medicine to address challenges associated with surgical biopsies," said
Biocept's Senior Vice President and Chief Science Officer
"With broad IP protection across our platform, we are well positioned to
capitalize on the movement to the liquid biopsy, which can save money
for the healthcare system and most importantly help patients qualify for
treatments that can save or prolong their life," added Biocept's
President and Chief Executive Officer
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to economic benefits for the
healthcare system, improvement of outcomes, our impact on diagnostic
strategies and planned future offerings, such statements are
forward-looking, and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The reader is
cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous risk factors as set forth in
our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150601005335/en/
Investor Contact:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media